Melbourne, Australia, 3rd June 2021. Akaal Pharma Pty Limited (Akaal Pharma) today announced that it is developing novel multimodal action Spingosine-1-Phosphate receptor subtype-1 (S1P1) modulator and lead topical drug candidate “AKP-11” for pruritus and inflammation. AKP-11 downmodulate the cytokines implicated in pruritic skin diseases and was safe and well tolerated in two of our Phase-1 studies when the AKP-11 was applied to subjects with psoriasis and atopic dermatitis. There was significant efficacy recorded with reduction in application site plaques and lesions along with the reduction in pruritus. Akaal Pharma will advance the AKP-11 in Phase-2 clinical trial to treat the atopic dermatitis and prurigo nodularis patients with moderate to severe pruritus.
The pruritus (itching) is debilitating disease associated with several inflammatory skin diseases. Pruritus provokes the desire to itch resulting in worsening of the lesions in several skin indications those include dermatitis (atopic dermatitis, contact dermatitis), psoriasis, prurigo nodularis. Pruritus remains a significant global problem and a multimodal action drug treating the pruritus and underlying inflammation relieving the disease symptoms effectively is the need of time where we believe AKP-11 will fill the gap.
“We continue to actively prioritize and expand our developmental programs to serve the wider global community those are suffering and where there is need of safe and effective treatment,” said Chairman of Akaal Pharma Mr B. S. Sandhu.
About Akaal Pharma Pty Ltd
Akaal Pharma is a private clinical-stage, Australian biotech company focused on advancing the clinical development of its internally discovered topical and oral small molecule drug candidates for treating inflammatory, autoimmune, neuronal and vascular diseases specifically pruritus, neuropathic pain, atopic dermatitis, psoriasis, alopecia areata, multiple sclerosis, ulcerative colitis and other diseases. For more information, please visit www.akaalpharma.com
Contacts
Akaal Pharma Pty Ltd
Dr Damian Grobelny and Gurmit S Gill, Akaal Pharma Pty Ltd, #301E, Thomas Cherry Building, La Trobe University, Bundoora, VIC-3083, Australia. Tel: +61-3-9479-2584. Email: info@akaalpharma.com
Disclaimer:
Certain statements in this new release concerning Akaal Pharma business are considered “forward looking statements”. Any or all the forward-looking statements in this press release can be affected by inaccurate assumptions. Akaal Pharma undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.